Drug Search Results
More Filters [+]

Spiradoline

Alternative Names: spiradoline
Latest Update: 2022-03-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: OPRK Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Spiradoline

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Bipolar Disorder

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

B1071004

P1

Completed

Bipolar Disorder

2009-12-01

Recent News Events